cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kodiak Sciences Inc
8 own
9 watching
Current Price
$6.01
$0.03
(0.5%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
314.53M
52-Week High
52-Week High
12.8
52-Week Low
52-Week Low
4.25
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization314.53M
icon52-Week High12.8
icon52-Week Low4.25
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio--
What does the Kodiak Sciences Inc do?
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Read More
How much money does Kodiak Sciences Inc make?
News & Events about Kodiak Sciences Inc.
PR Newswire
1month ago
Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting PR Newswire PALO ALTO, Calif., April 21, 2023 PALO ALTO, Calif., April...
PR Newswire
3 months ago
Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer...
Ticker Report
5 months ago
Kodiak Sciences Inc. (NASDAQ:KOD Get Rating) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 2,470,000 shares, a decrease of 9.2% from the November 15th total of 2,720,000 shares. Based on an average trading volume ...
Zolmax
5 months ago
Kodiak Sciences Inc. (NASDAQ:KOD Get Rating) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 2,720,000 shares, a decrease of 10.5% from the October 31st total of 3,040,000 shares. Based on an average ...
Ticker Report
8 months ago
Blueshift Asset Management LLC purchased a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD Get Rating) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 26,897 shares of the companys ...
Frequently Asked Questions
Frequently Asked Questions
What is Kodiak Sciences Inc share price today?
plus_minus_icon
Can Indians buy Kodiak Sciences Inc shares?
plus_minus_icon
How can I buy Kodiak Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Kodiak Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Kodiak Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Kodiak Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Kodiak Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Kodiak Sciences Inc?
plus_minus_icon
What percentage is Kodiak Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Kodiak Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.01
$0.03
(0.5%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SUTRO BIOPHARMA INC
SUTRO BIOPHARMA INC
$4.90
$-0.16 (-3.16 %)
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.35
$0.03 (0.47 %)
CABALETTA BIO INC
CABALETTA BIO INC
$9.02
$-0.40 (-4.25 %)
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC
$6.81
$0.30 (4.61 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
SUTRO BIOPHARMA INC
SUTRO BIOPHARMA INC
$4.90
$-0.16 (-3.16 %)
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.35
$0.03 (0.47 %)
CABALETTA BIO INC
CABALETTA BIO INC
$9.02
$-0.40 (-4.25 %)
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC
$6.81
$0.30 (4.61 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00